- Home
- VERX vs GLUE Comparison
VERX vs GLUE Comparison
Compare VERX & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VERX | GLUE |
|---|---|---|
| Founded | 1978 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VERX | GLUE |
|---|---|---|
| Price | $11.71 | $23.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | $24.25 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $748,444,000.00 | $123,672,000.00 |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $11.61 | $2.45 |
| P/E Ratio | $302.25 | ★ $72.42 |
| Revenue Growth | 12.25 | ★ 63.54 |
| 52 Week Low | $10.21 | $4.12 |
| 52 Week High | $34.54 | $25.77 |
Technical Indicators
Market Signals| Indicator | VERX | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 52.14 |
| Support Level | $11.58 | $17.35 |
| Resistance Level | $13.50 | $25.45 |
| Average True Range (ATR) | 0.65 | 1.54 |
| MACD | -0.14 | -0.25 |
| Stochastic Oscillator | 32.25 | 43.57 |
Price Performance
Historical ComparisonAbout VERX Vertex Inc.
Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).